The role of proton pump inhibitors in NSAID - Associated gastropathy and upper gastrointestinal symptoms

Reviews in Gastroenterological Disorders

Volumn 3, Issue SUPPL. 4, 2003, Pages

  Laine, Loren ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cyclooxygenase inhibitors; Gastrointestinal; NSAIDs; Proton pump inhibitors; Ulcers

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; SUCRALFATE; WARFARIN;

ABDOMINAL PAIN; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; MULTIPLE DRUG DOSE; PATIENT COMPLIANCE; RISK FACTOR; SINGLE DRUG DOSE; STOMACH EROSION; STOMACH ULCER;

ANTACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DYSPEPSIA; HUMANS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS;

EID: 0346271502     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Talley NJ, Evans JM, Fleming KC, et al. Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly. Dig Dis Sci. 1995;40:1345-1350.
2. Laine L. Approaches to NSAID use in the high-risk patient. Gastroenterology. 2001;120:594-606.
3. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology. 1999;117:776-783.
4. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:241-249.
5. Silverstein F, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA. 2000;284:1247-1255.
6. FDA Arthritis Advisory Committee meeting. February 7, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm.
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520-1528.
8. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-1187.
9. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low dose aspirin. Am J Gastroenterol. 2000;95:2218-2224.
10. Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal anti-inflammatory drugs. J Rheumatol. 2002; 29:804-812.
11. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115:787-796.
12. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000; 160:2093-2099.
13. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834-849.
14. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310:827-830.
15. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001; 52:563-571.)
16. Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989; 11:158-62.
17. Straus WL, Ofman JJ, MacLean C, et al. Do NSAIDs cause dyspepsia? A meta-analysis evaluating alternative dyspepsia definitions. Am J Gastroenterol. 2002;97:1951-1958.
18. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 1987; 28:527-532.
19. Holvoet J, Terriere L, Van Hee W, et al. Relation of upper gastrointestinal bleeding to nonsteroidal anti-inflammatory drugs and aspirin: a case control study. Gut. 1991;32:730-734.
20. Lancaster-Smith MJ, Jaderberg ME, Jackson DA. Ranitidine in the treatment of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulcers. Gut. 1991;32:252-255.
21. Robinson MG, Griffin JW, Bowers J, et al. Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Dig Dis Sci. 1989;34:424-428.
22. Ehsanullah RSB, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. Br Med J. 1988;297:1017-1021.
23. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med. 1996; 334:1435-1439.
24. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritic patients taking NSAIDs. Ann Intern Med. 1993;119:257-262.
25. Agrawal NM, van Kerckhove HEJM, Erhardt LJ, Geis SG. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one-year study. Dig Dis Sci. 1995;40:1125-1131.
26. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind multicenter study. Am J Gastroenterol. 1996;91:223-227.
27. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med. 1995;123:344-350.
28. Agrawal NM, Cladwell J, Kivitz AJ, et al. Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. Clin Ther. 1999;21:659.
29. Manniche C, Malchow-Moller A, Andersen JR, et al. Randomised study of the influence of nonsteroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Gut. 1987;28:226-229.
30. Bianchi Porro G, Iazzaroni M, Manzionna G, Petrillo M. Omeprazole and sucralfate in the treatment of NSAID-induced gastric and duodenal ulcer. Aliment Pharmacol Ther. 1998;12:355-360.
31. Miglioli M, Bianchi Porro G, Vaira D, et al. Prevention with sucralfate gel of NSAID-induced gastroduodenal damage in arthritic patients. Am J Gastroenterol. 1996;91:2367-2371.
32. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med. 1991;115:195-200.
33. Bianchi Porro G, Parente F, Imbesi V, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users: response to omeprazole dual therapy. Gut. 1996;39:22-26.
34. Lai KC, Lau CS, Ip WY, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2003: 17:799-805.
35. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobcater pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Lancet. 1998;352:1016-1021.
36. Chan FKL, Sung JJY, Chung SCS, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975-979.
37. Chan FKL, To KFT, Wu JCY, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with nonsteroidal anti-inflammatory drugs: a randomized trial. Lancet. 2002;359:9-13.
38. Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac-associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomized, double blind, placebo controlled trial. Gut. 2002;51:329-335.
39. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:719-726.
40. Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. Arch Intern Med. 2000;160:1455-1461.
41. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 1998;338:727-734.
42. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of non-steroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002;162:169-175.
43. Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998;12:135-140.
44. Eckstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy: a Nordic multicentre study. Scand J Gastroenterol. 1996;31:753-758.
45. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med. 2001;344:967-973.
46. Lai KC, Lam SK, Chu M et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033-2038.
47. Van Groenendael JHLM, Markusses HM, Dijkmans BAC, Breedveld FC. The effect of ranitidine on NSAID-related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol. 1996;15:450-456.
48. Caldwell JR, Roth SH, Wu WC, et al. Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med. 1987;83(suppl 3B):74-82.
49. Yeomans ND, Hawkey CJ, Jones R, et al. Esomeprazole provides effective control of NSAID-associated upper GI symptoms in patients contining to take NSAIDs. Gastroenterology. 2003;124(suppl 1):A-107.
50. Laheij RJF, Van Rossum LGM, Jansen JBMJ, Verheugt FWA. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther. 2003;18:109-115.
51. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with non-selective NSAID or coxib use. Gastroenterology. 2003;124:288-292.
52. Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation. 2001;104:2280-2288.
53. Goldstein JL, Eisen GM, Burke TA, et al. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther. 2002;16:809-827.
54. Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med. 2000;160:2998-3003.
55. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002;347:2104-2110.
56. Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D, Brett C, Reicin A. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002;123:1006-1012.
57. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115:787-796.
58. Lanza LL, Walker AM, Bortnichak EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years. A large health maintenance organization cohort study. Arch Intern Med. 1995;155:1371-1377.
59. Shorr RI, Ray WA. Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665-1670.
60. Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol. 2002; 53:173-181.
61. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.